The global heparin market size is expected to reach USD 9.03 billion by 2030, expanding at a CAGR of 2.7% from 2024 to 2030. The increasing geriatric population and heightened demand for transfusions are key factors propelling the market growth. Moreover, the outbreak of COVID-19 has further propelled the market growth. For instance, as per The Lancet Journal in 2022, the demand for heparin exacerbated attributable to its use in COVID-19 patients for thromboprophylaxis. ![Global Heparin Market]( "Global Heparin Market")
Increasing demand for blood components, transfusion, and plasma derivatives in the treatment of infectious diseases is expected to drive the market. For instance, according to American Red Cross in 2022, around 16 million blood components are transfused each year in the U.S. Furthermore, the surge in the number of surgeries that were delayed due to the COVID-19 pandemic has further escalated the demand for heparin for blood-clot prevention.
The growing geriatric population is estimated to fuel the market growth. According to United Nations, it was estimated that, in 2020, there were around 727 million people with ages above 60 years worldwide. In addition, the percentage share of the aged population above 65 years is estimated to increase from 9.3% in 2020 to 16% in 2050. The geriatric population has a higher rate of complex surgeries and thus is anticipated to propel the demand for heparin as an anticoagulant, as this population has a significantly higher rate of developing blood clots and related conditions such as deep vein thrombosis.
The growing number of surgeries is a key factor accelerating the demand for whole blood and transfusions. For instance, the annual number of major surgeries performed globally has reached 310 million, 40 to 50 million surgeries performed in the U.S., and around 20 million were performed in Europe in 2020. These surgeries are projected to escalate the demand for heparin.
The competitive rivalry in the marketplace is expected to be moderate due to changing dynamics towards oral anticoagulants. The involvement of players in discovering novel routes of administration for anticoagulants such as heparin is expected to change the market scenario over the forecast period. The rising number of players offering generics also increases competitive rivalry.
Increasing demand for blood components, transfusion, and plasma derivatives in the treatment of infectious diseases is expected to drive the market. For instance, according to American Red Cross in 2022, around 16 million blood components are transfused each year in the U.S. Furthermore, the surge in the number of surgeries that were delayed due to the COVID-19 pandemic has further escalated the demand for heparin for blood-clot prevention.
The growing geriatric population is estimated to fuel the market growth. According to United Nations, it was estimated that, in 2020, there were around 727 million people with ages above 60 years worldwide. In addition, the percentage share of the aged population above 65 years is estimated to increase from 9.3% in 2020 to 16% in 2050. The geriatric population has a higher rate of complex surgeries and thus is anticipated to propel the demand for heparin as an anticoagulant, as this population has a significantly higher rate of developing blood clots and related conditions such as deep vein thrombosis.
The growing number of surgeries is a key factor accelerating the demand for whole blood and transfusions. For instance, the annual number of major surgeries performed globally has reached 310 million, 40 to 50 million surgeries performed in the U.S., and around 20 million were performed in Europe in 2020. These surgeries are projected to escalate the demand for heparin.
The competitive rivalry in the marketplace is expected to be moderate due to changing dynamics towards oral anticoagulants. The involvement of players in discovering novel routes of administration for anticoagulants such as heparin is expected to change the market scenario over the forecast period. The rising number of players offering generics also increases competitive rivalry.
Heparin Market Report Highlights
- The Low Molecular Weight Heparin (LMWH) segment held the largest revenue share in 2023 owing to its high prescription rate and demand
- The subcutaneous route of administration segment held the largest revenue share in 2023 owing to its cost-effective nature and easier procedure for administration
- The coronary artery disease segment dominated the market in 2022 owing to the rising incidence of coronary artery disease and increased use of heparin injection in hospitalized patients
- The outpatient segment is expected to hold the largest revenue share in 2023 owing to the initiatives undertaken by hospitals for outpatient services and the increased preference of patients for outpatient treatment
- Porcine-derived heparin is expected to dominate the market due to its use in the production of low molecular weight heparin
- Asia-Pacific is expected to exhibit the fastest growth over the forecast period due to the growing establishment of healthcare, and a large population base
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Route of administration
1.2.3. Application
1.2.4. End-use
1.2.5. Source
1.2.6. Regional scope
1.2.7. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia-Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Type
1.2.2. Route of administration
1.2.3. Application
1.2.4. End-use
1.2.5. Source
1.2.6. Regional scope
1.2.7. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia-Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type
2.2.2. Route of Administration
2.2.3. Application
2.2.4. End-use
2.2.5. Source
2.2.6. Regional outlook
2.3. Competitive Insights
2.2. Segment Outlook
2.2.1. Type
2.2.2. Route of Administration
2.2.3. Application
2.2.4. End-use
2.2.5. Source
2.2.6. Regional outlook
2.3. Competitive Insights
Chapter 3. Heparin Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of chronic diseases
3.2.1.2. Growing demand for whole blood and blood components transfusion
3.2.1.3. Increasing geriatric population
3.2.1.4. High usage of plasma in the pharmaceutical industry
3.2.2. Market restraint analysis
3.2.2.1. Risk of blood-transmitted diseases and an increasing number of blood substitutes
3.2.2.2. Emerging oral anticoagulants
3.3. Heparin Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of chronic diseases
3.2.1.2. Growing demand for whole blood and blood components transfusion
3.2.1.3. Increasing geriatric population
3.2.1.4. High usage of plasma in the pharmaceutical industry
3.2.2. Market restraint analysis
3.2.2.1. Risk of blood-transmitted diseases and an increasing number of blood substitutes
3.2.2.2. Emerging oral anticoagulants
3.3. Heparin Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Heparin Market: Type Estimates & Trend Analysis
4.1. Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Heparin Market by Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Low Molecular Weight Heparin
4.4.1.1. Market estimates and forecasts, 2018-2030 (USD Million)
4.4.2. Ultra-low Molecular Weight Heparin
4.4.2.1. Market estimates and forecasts, 2018-2030 (USD Million)
4.4.3. Unfractionated Heparin
4.4.3.1. Market estimates and forecasts, 2018-2030 (USD Million)
4.2. Segment Dashboard
4.3. Global Heparin Market by Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Low Molecular Weight Heparin
4.4.1.1. Market estimates and forecasts, 2018-2030 (USD Million)
4.4.2. Ultra-low Molecular Weight Heparin
4.4.2.1. Market estimates and forecasts, 2018-2030 (USD Million)
4.4.3. Unfractionated Heparin
4.4.3.1. Market estimates and forecasts, 2018-2030 (USD Million)
Chapter 5. Heparin Market: Route of Administration Estimates & Trend Analysis
5.1. Route of Administration Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Heparin Market by Route of Administration Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Intravenous
5.4.1.1. Market estimates and forecasts, 2018-2030 (USD Million)
5.4.2. Subcutaneous
5.4.2.1. Market estimates and forecasts, 2018-2030 (USD Million)
5.2. Segment Dashboard
5.3. Global Heparin Market by Route of Administration Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Intravenous
5.4.1.1. Market estimates and forecasts, 2018-2030 (USD Million)
5.4.2. Subcutaneous
5.4.2.1. Market estimates and forecasts, 2018-2030 (USD Million)
Chapter 6. Heparin Market: Application Estimates & Trend Analysis
6.1. Application Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Heparin Market by Application Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Venous Thromboembolism
6.4.1.1. Market estimates and forecasts, 2018-2030 (USD Million)
6.4.2. Atrial Fibrillation
6.4.2.1. Market estimates and forecasts, 2018-2030 (USD Million)
6.4.3. Renal Impairment
6.4.3.1. Market estimates and forecasts, 2018-2030 (USD Million)
6.4.4. Coronary Artery Disease
6.4.4.1. Market estimates and forecasts, 2018-2030 (USD Million)
6.4.5. Others
6.4.5.1. Market estimates and forecasts, 2018-2030 (USD Million)
6.2. Segment Dashboard
6.3. Global Heparin Market by Application Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Venous Thromboembolism
6.4.1.1. Market estimates and forecasts, 2018-2030 (USD Million)
6.4.2. Atrial Fibrillation
6.4.2.1. Market estimates and forecasts, 2018-2030 (USD Million)
6.4.3. Renal Impairment
6.4.3.1. Market estimates and forecasts, 2018-2030 (USD Million)
6.4.4. Coronary Artery Disease
6.4.4.1. Market estimates and forecasts, 2018-2030 (USD Million)
6.4.5. Others
6.4.5.1. Market estimates and forecasts, 2018-2030 (USD Million)
Chapter 7. Heparin Market: End-use Estimates & Trend Analysis
7.1. End-use Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global Heparin Market by End-use Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Outpatient
7.4.1.1. Market estimates and forecasts, 2018-2030 (USD Million)
7.4.2. Inpatient
7.4.2.1. Market estimates and forecasts, 2018-2030 (USD Million)
7.2. Segment Dashboard
7.3. Global Heparin Market by End-use Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Outpatient
7.4.1.1. Market estimates and forecasts, 2018-2030 (USD Million)
7.4.2. Inpatient
7.4.2.1. Market estimates and forecasts, 2018-2030 (USD Million)
Chapter 8. Heparin Market: Source Estimates & Trend Analysis
8.1. Source Market Share, 2023 & 2030
8.2. Segment Dashboard
8.3. Global Heparin Market by Source Outlook
8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
8.4.1. Porcine
8.4.1.1. Market estimates and forecasts, 2018-2030 (USD Million)
8.4.2. Bovine
8.4.2.1. Market estimates and forecasts, 2018-2030 (USD Million)
8.4.3. Others
8.4.3.1. Market estimates and forecasts, 2018-2030 (USD Million)
8.2. Segment Dashboard
8.3. Global Heparin Market by Source Outlook
8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
8.4.1. Porcine
8.4.1.1. Market estimates and forecasts, 2018-2030 (USD Million)
8.4.2. Bovine
8.4.2.1. Market estimates and forecasts, 2018-2030 (USD Million)
8.4.3. Others
8.4.3.1. Market estimates and forecasts, 2018-2030 (USD Million)
Chapter 9. Heparin Market: Regional Estimates & Trend Analysis
9.1. Regional Market Share Analysis, 2023 & 2030
9.2. Regional Market Dashboard
9.3. Global Regional Market Snapshot
9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
9.5. North America
9.5.1. U.S.
9.5.1.1. Key country dynamics
9.5.1.2. Regulatory framework/ reimbursement structure
9.5.1.3. Competitive scenario
9.5.1.4. U.S. market estimates and forecasts, 2018-2030 (USD Million)
9.5.2. Canada
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework/ reimbursement structure
9.5.2.3. Competitive scenario
9.5.2.4. Canada market estimates and forecasts, 2018-2030 (USD Million)
9.6. Europe
9.6.1. UK
9.6.1.1. Key country dynamics
9.6.1.2. Regulatory framework/ reimbursement structure
9.6.1.3. Competitive scenario
9.6.1.4. UK market estimates and forecasts, 2018-2030 (USD Million)
9.6.2. Germany
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework/ reimbursement structure
9.6.2.3. Competitive scenario
9.6.2.4. Germany market estimates and forecasts, 2018-2030 (USD Million)
9.6.3. France
9.6.3.1. Key country dynamics
9.6.3.2. Regulatory framework/ reimbursement structure
9.6.3.3. Competitive scenario
9.6.3.4. France market estimates and forecasts, 2018-2030 (USD Million)
9.6.4. Italy
9.6.4.1. Key country dynamics
9.6.4.2. Regulatory framework/ reimbursement structure
9.6.4.3. Competitive scenario
9.6.4.4. Italy market estimates and forecasts, 2018-2030 (USD Million)
9.6.5. Spain
9.6.5.1. Key country dynamics
9.6.5.2. Regulatory framework/ reimbursement structure
9.6.5.3. Competitive scenario
9.6.5.4. Spain market estimates and forecasts, 2018-2030 (USD Million)
9.6.6. Norway
9.6.6.1. Key country dynamics
9.6.6.2. Regulatory framework/ reimbursement structure
9.6.6.3. Competitive scenario
9.6.6.4. Norway market estimates and forecasts, 2018-2030 (USD Million)
9.6.7. Sweden
9.6.7.1. Key country dynamics
9.6.7.2. Regulatory framework/ reimbursement structure
9.6.7.3. Competitive scenario
9.6.7.4. Sweden market estimates and forecasts, 2018-2030 (USD Million)
9.6.8. Denmark
9.6.8.1. Key country dynamics
9.6.8.2. Regulatory framework/ reimbursement structure
9.6.8.3. Competitive scenario
9.6.8.4. Denmark market estimates and forecasts, 2018-2030 (USD Million)
9.7. Asia-Pacific
9.7.1. Japan
9.7.1.1. Key country dynamics
9.7.1.2. Regulatory framework/ reimbursement structure
9.7.1.3. Competitive scenario
9.7.1.4. Japan market estimates and forecasts, 2018-2030 (USD Million)
9.7.2. China
9.7.2.1. Key country dynamics
9.7.2.2. Regulatory framework/ reimbursement structure
9.7.2.3. Competitive scenario
9.7.2.4. China market estimates and forecasts, 2018-2030 (USD Million)
9.7.3. India
9.7.3.1. Key country dynamics
9.7.3.2. Regulatory framework/ reimbursement structure
9.7.3.3. Competitive scenario
9.7.3.4. India market estimates and forecasts, 2018-2030 (USD Million)
9.7.4. Australia
9.7.4.1. Key country dynamics
9.7.4.2. Regulatory framework/ reimbursement structure
9.7.4.3. Competitive scenario
9.7.4.4. Australia market estimates and forecasts, 2018-2030 (USD Million)
9.7.5. South Korea
9.7.5.1. Key country dynamics
9.7.5.2. Regulatory framework/ reimbursement structure
9.7.5.3. Competitive scenario
9.7.5.4. South Korea market estimates and forecasts, 2018-2030 (USD Million)
9.7.6. Thailand
9.7.6.1. Key country dynamics
9.7.6.2. Regulatory framework/ reimbursement structure
9.7.6.3. Competitive scenario
9.7.6.4. Thailand market estimates and forecasts, 2018-2030 (USD Million)
9.8. Latin America
9.8.1. Brazil
9.8.1.1. Key country dynamics
9.8.1.2. Regulatory framework/ reimbursement structure
9.8.1.3. Competitive scenario
9.8.1.4. Brazil market estimates and forecasts, 2018-2030 (USD Million)
9.8.2. Mexico
9.8.2.1. Key country dynamics
9.8.2.2. Regulatory framework/ reimbursement structure
9.8.2.3. Competitive scenario
9.8.2.4. Mexico market estimates and forecasts, 2018-2030 (USD Million)
9.8.3. Argentina
9.8.3.1. Key country dynamics
9.8.3.2. Regulatory framework/ reimbursement structure
9.8.3.3. Competitive scenario
9.8.3.4. Argentina market estimates and forecasts, 2018-2030 (USD Million)
9.9. MEA
9.9.1. South Africa
9.9.1.1. Key country dynamics
9.9.1.2. Regulatory framework/ reimbursement structure
9.9.1.3. Competitive scenario
9.9.1.4. South Africa market estimates and forecasts, 2018-2030 (USD Million)
9.9.2. Saudi Arabia
9.9.2.1. Key country dynamics
9.9.2.2. Regulatory framework/ reimbursement structure
9.9.2.3. Competitive scenario
9.9.2.4. Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
9.9.3. UAE
9.9.3.1. Key country dynamics
9.9.3.2. Regulatory framework/ reimbursement structure
9.9.3.3. Competitive scenario
9.9.3.4. UAE market estimates and forecasts, 2018-2030 (USD Million)
9.9.4. Kuwait
9.9.4.1. Key country dynamics
9.9.4.2. Regulatory framework/ reimbursement structure
9.9.4.3. Competitive scenario
9.9.4.4. Kuwait market estimates and forecasts, 2018-2030 (USD Million)
9.2. Regional Market Dashboard
9.3. Global Regional Market Snapshot
9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
9.5. North America
9.5.1. U.S.
9.5.1.1. Key country dynamics
9.5.1.2. Regulatory framework/ reimbursement structure
9.5.1.3. Competitive scenario
9.5.1.4. U.S. market estimates and forecasts, 2018-2030 (USD Million)
9.5.2. Canada
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework/ reimbursement structure
9.5.2.3. Competitive scenario
9.5.2.4. Canada market estimates and forecasts, 2018-2030 (USD Million)
9.6. Europe
9.6.1. UK
9.6.1.1. Key country dynamics
9.6.1.2. Regulatory framework/ reimbursement structure
9.6.1.3. Competitive scenario
9.6.1.4. UK market estimates and forecasts, 2018-2030 (USD Million)
9.6.2. Germany
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework/ reimbursement structure
9.6.2.3. Competitive scenario
9.6.2.4. Germany market estimates and forecasts, 2018-2030 (USD Million)
9.6.3. France
9.6.3.1. Key country dynamics
9.6.3.2. Regulatory framework/ reimbursement structure
9.6.3.3. Competitive scenario
9.6.3.4. France market estimates and forecasts, 2018-2030 (USD Million)
9.6.4. Italy
9.6.4.1. Key country dynamics
9.6.4.2. Regulatory framework/ reimbursement structure
9.6.4.3. Competitive scenario
9.6.4.4. Italy market estimates and forecasts, 2018-2030 (USD Million)
9.6.5. Spain
9.6.5.1. Key country dynamics
9.6.5.2. Regulatory framework/ reimbursement structure
9.6.5.3. Competitive scenario
9.6.5.4. Spain market estimates and forecasts, 2018-2030 (USD Million)
9.6.6. Norway
9.6.6.1. Key country dynamics
9.6.6.2. Regulatory framework/ reimbursement structure
9.6.6.3. Competitive scenario
9.6.6.4. Norway market estimates and forecasts, 2018-2030 (USD Million)
9.6.7. Sweden
9.6.7.1. Key country dynamics
9.6.7.2. Regulatory framework/ reimbursement structure
9.6.7.3. Competitive scenario
9.6.7.4. Sweden market estimates and forecasts, 2018-2030 (USD Million)
9.6.8. Denmark
9.6.8.1. Key country dynamics
9.6.8.2. Regulatory framework/ reimbursement structure
9.6.8.3. Competitive scenario
9.6.8.4. Denmark market estimates and forecasts, 2018-2030 (USD Million)
9.7. Asia-Pacific
9.7.1. Japan
9.7.1.1. Key country dynamics
9.7.1.2. Regulatory framework/ reimbursement structure
9.7.1.3. Competitive scenario
9.7.1.4. Japan market estimates and forecasts, 2018-2030 (USD Million)
9.7.2. China
9.7.2.1. Key country dynamics
9.7.2.2. Regulatory framework/ reimbursement structure
9.7.2.3. Competitive scenario
9.7.2.4. China market estimates and forecasts, 2018-2030 (USD Million)
9.7.3. India
9.7.3.1. Key country dynamics
9.7.3.2. Regulatory framework/ reimbursement structure
9.7.3.3. Competitive scenario
9.7.3.4. India market estimates and forecasts, 2018-2030 (USD Million)
9.7.4. Australia
9.7.4.1. Key country dynamics
9.7.4.2. Regulatory framework/ reimbursement structure
9.7.4.3. Competitive scenario
9.7.4.4. Australia market estimates and forecasts, 2018-2030 (USD Million)
9.7.5. South Korea
9.7.5.1. Key country dynamics
9.7.5.2. Regulatory framework/ reimbursement structure
9.7.5.3. Competitive scenario
9.7.5.4. South Korea market estimates and forecasts, 2018-2030 (USD Million)
9.7.6. Thailand
9.7.6.1. Key country dynamics
9.7.6.2. Regulatory framework/ reimbursement structure
9.7.6.3. Competitive scenario
9.7.6.4. Thailand market estimates and forecasts, 2018-2030 (USD Million)
9.8. Latin America
9.8.1. Brazil
9.8.1.1. Key country dynamics
9.8.1.2. Regulatory framework/ reimbursement structure
9.8.1.3. Competitive scenario
9.8.1.4. Brazil market estimates and forecasts, 2018-2030 (USD Million)
9.8.2. Mexico
9.8.2.1. Key country dynamics
9.8.2.2. Regulatory framework/ reimbursement structure
9.8.2.3. Competitive scenario
9.8.2.4. Mexico market estimates and forecasts, 2018-2030 (USD Million)
9.8.3. Argentina
9.8.3.1. Key country dynamics
9.8.3.2. Regulatory framework/ reimbursement structure
9.8.3.3. Competitive scenario
9.8.3.4. Argentina market estimates and forecasts, 2018-2030 (USD Million)
9.9. MEA
9.9.1. South Africa
9.9.1.1. Key country dynamics
9.9.1.2. Regulatory framework/ reimbursement structure
9.9.1.3. Competitive scenario
9.9.1.4. South Africa market estimates and forecasts, 2018-2030 (USD Million)
9.9.2. Saudi Arabia
9.9.2.1. Key country dynamics
9.9.2.2. Regulatory framework/ reimbursement structure
9.9.2.3. Competitive scenario
9.9.2.4. Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
9.9.3. UAE
9.9.3.1. Key country dynamics
9.9.3.2. Regulatory framework/ reimbursement structure
9.9.3.3. Competitive scenario
9.9.3.4. UAE market estimates and forecasts, 2018-2030 (USD Million)
9.9.4. Kuwait
9.9.4.1. Key country dynamics
9.9.4.2. Regulatory framework/ reimbursement structure
9.9.4.3. Competitive scenario
9.9.4.4. Kuwait market estimates and forecasts, 2018-2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Vendor Landscape
10.3.1. List of key distributors and channel partners
10.3.2. Key customers
10.3.3. Key company market share analysis, 2023
10.3.4. Pfizer Inc.
10.3.4.1. Company overview
10.3.4.2. Financial performance
10.3.4.3. Type benchmarking
10.3.4.4. Strategic initiatives
10.3.5. LEO Pharma A/S
10.3.5.1. Company overview
10.3.5.2. Financial performance
10.3.5.3. Type benchmarking
10.3.5.4. Strategic initiatives
10.3.6. Dr. Reddy’s Laboratories Ltd.
10.3.6.1. Company overview
10.3.6.2. Financial performance
10.3.6.3. Type benchmarking
10.3.6.4. Strategic initiatives
10.3.7. GlaxoSmithKline plc
10.3.7.1. Company overview
10.3.7.2. Financial performance
10.3.7.3. Type benchmarking
10.3.7.4. Strategic initiatives
10.3.8. Sanofi
10.3.8.1. Company overview
10.3.8.2. Financial performance
10.3.8.3. Type benchmarking
10.3.8.4. Strategic initiatives
10.3.9. Aspen Holdings
10.3.9.1. Company overview
10.3.9.2. Financial performance
10.3.9.3. Type benchmarking
10.3.9.4. Strategic initiatives
10.3.10. Fresenius SE & Co. KGaA
10.3.10.1. Company overview
10.3.10.2. Financial performance
10.3.10.3. Type benchmarking
10.3.10.4. Strategic initiatives
10.3.11. B. Braun Medical, Inc.
10.3.11.1. Company overview
10.3.11.2. Financial performance
10.3.11.3. Type benchmarking
10.3.11.4. Strategic initiatives
10.3.12. Sandoz (Novartis AG)
10.3.12.1. Company overview
10.3.12.2. Financial performance
10.3.12.3. Type benchmarking
10.3.12.4. Strategic initiatives
10.2. Company/Competition Categorization
10.3. Vendor Landscape
10.3.1. List of key distributors and channel partners
10.3.2. Key customers
10.3.3. Key company market share analysis, 2023
10.3.4. Pfizer Inc.
10.3.4.1. Company overview
10.3.4.2. Financial performance
10.3.4.3. Type benchmarking
10.3.4.4. Strategic initiatives
10.3.5. LEO Pharma A/S
10.3.5.1. Company overview
10.3.5.2. Financial performance
10.3.5.3. Type benchmarking
10.3.5.4. Strategic initiatives
10.3.6. Dr. Reddy’s Laboratories Ltd.
10.3.6.1. Company overview
10.3.6.2. Financial performance
10.3.6.3. Type benchmarking
10.3.6.4. Strategic initiatives
10.3.7. GlaxoSmithKline plc
10.3.7.1. Company overview
10.3.7.2. Financial performance
10.3.7.3. Type benchmarking
10.3.7.4. Strategic initiatives
10.3.8. Sanofi
10.3.8.1. Company overview
10.3.8.2. Financial performance
10.3.8.3. Type benchmarking
10.3.8.4. Strategic initiatives
10.3.9. Aspen Holdings
10.3.9.1. Company overview
10.3.9.2. Financial performance
10.3.9.3. Type benchmarking
10.3.9.4. Strategic initiatives
10.3.10. Fresenius SE & Co. KGaA
10.3.10.1. Company overview
10.3.10.2. Financial performance
10.3.10.3. Type benchmarking
10.3.10.4. Strategic initiatives
10.3.11. B. Braun Medical, Inc.
10.3.11.1. Company overview
10.3.11.2. Financial performance
10.3.11.3. Type benchmarking
10.3.11.4. Strategic initiatives
10.3.12. Sandoz (Novartis AG)
10.3.12.1. Company overview
10.3.12.2. Financial performance
10.3.12.3. Type benchmarking
10.3.12.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 North America Heparin market, by region, 2018-2030 (USD Million)
Table 3 North America Heparin market, by type, 2018-2030 (USD Million)
Table 4 North America Heparin market, by route of administration, 2018-2030 (USD Million)
Table 5 North America Heparin market, by application, 2018-2030 (USD Million)
Table 6 North America Heparin market, by end-use, 2018-2030 (USD Million)
Table 7 North America Heparin market, by source, 2018-2030 (USD Million)
Table 8 U.S. Heparin market, by type, 2018-2030 (USD Million)
Table 9 U.S. Heparin market, by route of administration, 2018-2030 (USD Million)
Table 10 U.S. Heparin market, by application, 2018-2030 (USD Million)
Table 11 U.S. Heparin market, by end-use, 2018-2030 (USD Million)
Table 12 U.S. Heparin market, by source, 2018-2030 (USD Million)
Table 13 Canada Heparin market, by type, 2018-2030 (USD Million)
Table 14 Canada Heparin market, by route of administration, 2018-2030 (USD Million)
Table 15 Canada Heparin market, by application, 2018-2030 (USD Million)
Table 16 Canada Heparin market, by end-use, 2018-2030 (USD Million)
Table 17 Canada Heparin market, by source, 2018-2030 (USD Million)
Table 18 Europe Heparin market, by region, 2018-2030 (USD Million)
Table 19 Europe Heparin market, by type, 2018-2030 (USD Million)
Table 20 Europe Heparin market, by route of administration, 2018-2030 (USD Million)
Table 21 Europe Heparin market, by application, 2018-2030 (USD Million)
Table 22 Europe Heparin market, by end-use, 2018-2030 (USD Million)
Table 23 Europe Heparin market, by source, 2018-2030 (USD Million)
Table 24 Germany Heparin market, by type, 2018-2030 (USD Million)
Table 25 Germany Heparin market, by route of administration, 2018-2030 (USD Million)
Table 26 Germany Heparin market, by application, 2018-2030 (USD Million)
Table 27 Germany Heparin market, by end-use, 2018-2030 (USD Million)
Table 28 Germany Heparin market, by source, 2018-2030 (USD Million)
Table 29 UK Heparin market, by type, 2018-2030 (USD Million)
Table 30 UK Heparin market, by route of administration, 2018-2030 (USD Million)
Table 31 UK Heparin market, by application, 2018-2030 (USD Million)
Table 32 UK Heparin market, by end-use, 2018-2030 (USD Million)
Table 33 UK Heparin market, by source, 2018-2030 (USD Million)
Table 34 France Heparin market, by type, 2018-2030 (USD Million)
Table 35 France Heparin market, by route of administration, 2018-2030 (USD Million)
Table 36 France Heparin market, by application, 2018-2030 (USD Million)
Table 37 France Heparin market, by end-use, 2018-2030 (USD Million)
Table 38 France Heparin market, by source, 2018-2030 (USD Million)
Table 39 Italy Heparin market, by type, 2018-2030 (USD Million)
Table 40 Italy Heparin market, by route of administration, 2018-2030 (USD Million)
Table 41 Italy Heparin market, by application, 2018-2030 (USD Million)
Table 42 Italy Heparin market, by end-use, 2018-2030 (USD Million)
Table 43 Italy Heparin market, by source, 2018-2030 (USD Million)
Table 44 Spain Heparin market, by type, 2018-2030 (USD Million)
Table 45 Spain Heparin market, by route of administration, 2018-2030 (USD Million)
Table 46 Spain Heparin market, by application, 2018-2030 (USD Million)
Table 47 Spain Heparin market, by end-use, 2018-2030 (USD Million)
Table 48 Spain Heparin market, by source, 2018-2030 (USD Million)
Table 49 Denmark Heparin market, by type, 2018-2030 (USD Million)
Table 50 Denmark Heparin market, by route of administration, 2018-2030 (USD Million)
Table 51 Denmark Heparin market, by application, 2018-2030 (USD Million)
Table 52 Denmark Heparin market, by end-use, 2018-2030 (USD Million)
Table 53 Denmark Heparin market, by source, 2018-2030 (USD Million)
Table 54 Sweden Heparin market, by type, 2018-2030 (USD Million)
Table 55 Sweden Heparin market, by route of administration, 2018-2030 (USD Million)
Table 56 Sweden Heparin market, by application, 2018-2030 (USD Million)
Table 57 Sweden Heparin market, by end-use, 2018-2030 (USD Million)
Table 58 Sweden Heparin market, by source, 2018-2030 (USD Million)
Table 59 Norway Heparin market, by type, 2018-2030 (USD Million)
Table 60 Norway Heparin market, by route of administration, 2018-2030 (USD Million)
Table 61 Norway Heparin market, by application, 2018-2030 (USD Million)
Table 62 Norway Heparin market, by end-use, 2018-2030 (USD Million)
Table 63 Norway Heparin market, by source, 2018-2030 (USD Million)
Table 64 Asia-Pacific Heparin market, by region, 2018-2030 (USD Million)
Table 65 Asia-Pacific Heparin market, by type, 2018-2030 (USD Million)
Table 66 Asia-Pacific Heparin market, by route of administration, 2018-2030 (USD Million)
Table 67 Asia-Pacific Heparin market, by application, 2018-2030 (USD Million)
Table 68 Asia-Pacific Heparin market, by end-use, 2018-2030 (USD Million)
Table 69 Asia-Pacific Heparin market, by source, 2018-2030 (USD Million)
Table 70 China Heparin market, by type, 2018-2030 (USD Million)
Table 71 China Heparin market, by route of administration, 2018-2030 (USD Million)
Table 72 China Heparin market, by application, 2018-2030 (USD Million)
Table 73 China Heparin market, by end-use, 2018-2030 (USD Million)
Table 74 China Heparin market, by source, 2018-2030 (USD Million)
Table 75 Japan Heparin market, by type, 2018-2030 (USD Million)
Table 76 Japan Heparin market, by route of administration, 2018-2030 (USD Million)
Table 77 Japan Heparin market, by application, 2018-2030 (USD Million)
Table 78 Japan Heparin market, by end-use, 2018-2030 (USD Million)
Table 79 Japan Heparin market, by source, 2018-2030 (USD Million)
Table 80 India Heparin market, by type, 2018-2030 (USD Million)
Table 81 India Heparin market, by route of administration, 2018-2030 (USD Million)
Table 82 India Heparin market, by application, 2018-2030 (USD Million)
Table 83 India Heparin market, by end-use, 2018-2030 (USD Million)
Table 84 India Heparin market, by source, 2018-2030 (USD Million)
Table 85 South Korea Heparin market, by type, 2018-2030 (USD Million)
Table 86 South Korea Heparin market, by route of administration, 2018-2030 (USD Million)
Table 87 South Korea Heparin market, by application, 2018-2030 (USD Million)
Table 88 South Korea Heparin market, by end-use, 2018-2030 (USD Million)
Table 89 South Korea Heparin market, by source, 2018-2030 (USD Million)
Table 90 Australia Heparin market, by type, 2018-2030 (USD Million)
Table 91 Australia Heparin market, by route of administration, 2018-2030 (USD Million)
Table 92 Australia Heparin market, by application, 2018-2030 (USD Million)
Table 93 Australia Heparin market, by end-use, 2018-2030 (USD Million)
Table 94 Australia Heparin market, by source, 2018-2030 (USD Million)
Table 95 Thailand Heparin market, by type, 2018-2030 (USD Million)
Table 96 Thailand Heparin market, by route of administration, 2018-2030 (USD Million)
Table 97 Thailand Heparin market, by application, 2018-2030 (USD Million)
Table 98 Thailand Heparin market, by end-use, 2018-2030 (USD Million)
Table 99 Thailand Heparin market, by source, 2018-2030 (USD Million)
Table 100 Latin America Heparin market, by region, 2018-2030 (USD Million)
Table 101 Latin America Heparin market, by type, 2018-2030 (USD Million)
Table 102 Latin America Heparin market, by route of administration, 2018-2030 (USD Million)
Table 103 Latin America Heparin market, by application, 2018-2030 (USD Million)
Table 104 Latin America Heparin market, by end-use, 2018-2030 (USD Million)
Table 105 Latin America Heparin market, by source, 2018-2030 (USD Million)
Table 106 Brazil Heparin market, by type, 2018-2030 (USD Million)
Table 107 Brazil Heparin market, by route of administration, 2018-2030 (USD Million)
Table 108 Brazil Heparin market, by application, 2018-2030 (USD Million)
Table 109 Brazil Heparin market, by end-use, 2018-2030 (USD Million)
Table 110 Brazil Heparin market, by source, 2018-2030 (USD Million)
Table 111 Mexico Heparin market, by type, 2018-2030 (USD Million)
Table 112 Mexico Heparin market, by route of administration, 2018-2030 (USD Million)
Table 113 Mexico Heparin market, by application, 2018-2030 (USD Million)
Table 114 Mexico Heparin market, by end-use, 2018-2030 (USD Million)
Table 115 Mexico Heparin market, by source, 2018-2030 (USD Million)
Table 116 Argentina Heparin market, by type, 2018-2030 (USD Million)
Table 117 Argentina Heparin market, by route of administration, 2018-2030 (USD Million)
Table 118 Argentina Heparin market, by application, 2018-2030 (USD Million)
Table 119 Argentina Heparin market, by end-use, 2018-2030 (USD Million)
Table 120 Argentina Heparin market, by source, 2018-2030 (USD Million)
Table 121 MEA Heparin market, by region, 2018-2030 (USD Million)
Table 122 MEA Heparin market, by type, 2018-2030 (USD Million)
Table 123 MEA Heparin market, by route of administration, 2018-2030 (USD Million)
Table 124 MEA Heparin market, by application, 2018-2030 (USD Million)
Table 125 MEA Heparin market, by end-use, 2018-2030 (USD Million)
Table 126 MEA Heparin market, by source, 2018-2030 (USD Million)
Table 127 South Africa Heparin market, by type, 2018-2030 (USD Million)
Table 128 South Africa Heparin market, by route of administration, 2018-2030 (USD Million)
Table 129 South Africa Heparin market, by application, 2018-2030 (USD Million)
Table 130 South Africa Heparin market, by end-use, 2018-2030 (USD Million)
Table 131 South Africa Heparin market, by source, 2018-2030 (USD Million)
Table 132 Saudi Arabia Heparin market, by type, 2018-2030 (USD Million)
Table 133 Saudi Arabia Heparin market, by route of administration, 2018-2030 (USD Million)
Table 134 Saudi Arabia Heparin market, by application, 2018-2030 (USD Million)
Table 135 Saudi Arabia Heparin market, by end-use, 2018-2030 (USD Million)
Table 136 Saudi Arabia Heparin market, by source, 2018-2030 (USD Million)
Table 137 UAE Heparin market, by type, 2018-2030 (USD Million)
Table 138 UAE Heparin market, by route of administration, 2018-2030 (USD Million)
Table 139 UAE Heparin market, by application, 2018-2030 (USD Million)
Table 140 UAE Heparin market, by end-use, 2018-2030 (USD Million)
Table 141 UAE Heparin market, by source, 2018-2030 (USD Million)
Table 142 Kuwait Heparin market, by type, 2018-2030 (USD Million)
Table 143 Kuwait Heparin market, by route of administration, 2018-2030 (USD Million)
Table 144 Kuwait Heparin market, by application, 2018-2030 (USD Million)
Table 145 Kuwait Heparin market, by end-use, 2018-2030 (USD Million)
Table 146 Kuwait Heparin market, by source, 2018-2030 (USD Million)
Table 2 North America Heparin market, by region, 2018-2030 (USD Million)
Table 3 North America Heparin market, by type, 2018-2030 (USD Million)
Table 4 North America Heparin market, by route of administration, 2018-2030 (USD Million)
Table 5 North America Heparin market, by application, 2018-2030 (USD Million)
Table 6 North America Heparin market, by end-use, 2018-2030 (USD Million)
Table 7 North America Heparin market, by source, 2018-2030 (USD Million)
Table 8 U.S. Heparin market, by type, 2018-2030 (USD Million)
Table 9 U.S. Heparin market, by route of administration, 2018-2030 (USD Million)
Table 10 U.S. Heparin market, by application, 2018-2030 (USD Million)
Table 11 U.S. Heparin market, by end-use, 2018-2030 (USD Million)
Table 12 U.S. Heparin market, by source, 2018-2030 (USD Million)
Table 13 Canada Heparin market, by type, 2018-2030 (USD Million)
Table 14 Canada Heparin market, by route of administration, 2018-2030 (USD Million)
Table 15 Canada Heparin market, by application, 2018-2030 (USD Million)
Table 16 Canada Heparin market, by end-use, 2018-2030 (USD Million)
Table 17 Canada Heparin market, by source, 2018-2030 (USD Million)
Table 18 Europe Heparin market, by region, 2018-2030 (USD Million)
Table 19 Europe Heparin market, by type, 2018-2030 (USD Million)
Table 20 Europe Heparin market, by route of administration, 2018-2030 (USD Million)
Table 21 Europe Heparin market, by application, 2018-2030 (USD Million)
Table 22 Europe Heparin market, by end-use, 2018-2030 (USD Million)
Table 23 Europe Heparin market, by source, 2018-2030 (USD Million)
Table 24 Germany Heparin market, by type, 2018-2030 (USD Million)
Table 25 Germany Heparin market, by route of administration, 2018-2030 (USD Million)
Table 26 Germany Heparin market, by application, 2018-2030 (USD Million)
Table 27 Germany Heparin market, by end-use, 2018-2030 (USD Million)
Table 28 Germany Heparin market, by source, 2018-2030 (USD Million)
Table 29 UK Heparin market, by type, 2018-2030 (USD Million)
Table 30 UK Heparin market, by route of administration, 2018-2030 (USD Million)
Table 31 UK Heparin market, by application, 2018-2030 (USD Million)
Table 32 UK Heparin market, by end-use, 2018-2030 (USD Million)
Table 33 UK Heparin market, by source, 2018-2030 (USD Million)
Table 34 France Heparin market, by type, 2018-2030 (USD Million)
Table 35 France Heparin market, by route of administration, 2018-2030 (USD Million)
Table 36 France Heparin market, by application, 2018-2030 (USD Million)
Table 37 France Heparin market, by end-use, 2018-2030 (USD Million)
Table 38 France Heparin market, by source, 2018-2030 (USD Million)
Table 39 Italy Heparin market, by type, 2018-2030 (USD Million)
Table 40 Italy Heparin market, by route of administration, 2018-2030 (USD Million)
Table 41 Italy Heparin market, by application, 2018-2030 (USD Million)
Table 42 Italy Heparin market, by end-use, 2018-2030 (USD Million)
Table 43 Italy Heparin market, by source, 2018-2030 (USD Million)
Table 44 Spain Heparin market, by type, 2018-2030 (USD Million)
Table 45 Spain Heparin market, by route of administration, 2018-2030 (USD Million)
Table 46 Spain Heparin market, by application, 2018-2030 (USD Million)
Table 47 Spain Heparin market, by end-use, 2018-2030 (USD Million)
Table 48 Spain Heparin market, by source, 2018-2030 (USD Million)
Table 49 Denmark Heparin market, by type, 2018-2030 (USD Million)
Table 50 Denmark Heparin market, by route of administration, 2018-2030 (USD Million)
Table 51 Denmark Heparin market, by application, 2018-2030 (USD Million)
Table 52 Denmark Heparin market, by end-use, 2018-2030 (USD Million)
Table 53 Denmark Heparin market, by source, 2018-2030 (USD Million)
Table 54 Sweden Heparin market, by type, 2018-2030 (USD Million)
Table 55 Sweden Heparin market, by route of administration, 2018-2030 (USD Million)
Table 56 Sweden Heparin market, by application, 2018-2030 (USD Million)
Table 57 Sweden Heparin market, by end-use, 2018-2030 (USD Million)
Table 58 Sweden Heparin market, by source, 2018-2030 (USD Million)
Table 59 Norway Heparin market, by type, 2018-2030 (USD Million)
Table 60 Norway Heparin market, by route of administration, 2018-2030 (USD Million)
Table 61 Norway Heparin market, by application, 2018-2030 (USD Million)
Table 62 Norway Heparin market, by end-use, 2018-2030 (USD Million)
Table 63 Norway Heparin market, by source, 2018-2030 (USD Million)
Table 64 Asia-Pacific Heparin market, by region, 2018-2030 (USD Million)
Table 65 Asia-Pacific Heparin market, by type, 2018-2030 (USD Million)
Table 66 Asia-Pacific Heparin market, by route of administration, 2018-2030 (USD Million)
Table 67 Asia-Pacific Heparin market, by application, 2018-2030 (USD Million)
Table 68 Asia-Pacific Heparin market, by end-use, 2018-2030 (USD Million)
Table 69 Asia-Pacific Heparin market, by source, 2018-2030 (USD Million)
Table 70 China Heparin market, by type, 2018-2030 (USD Million)
Table 71 China Heparin market, by route of administration, 2018-2030 (USD Million)
Table 72 China Heparin market, by application, 2018-2030 (USD Million)
Table 73 China Heparin market, by end-use, 2018-2030 (USD Million)
Table 74 China Heparin market, by source, 2018-2030 (USD Million)
Table 75 Japan Heparin market, by type, 2018-2030 (USD Million)
Table 76 Japan Heparin market, by route of administration, 2018-2030 (USD Million)
Table 77 Japan Heparin market, by application, 2018-2030 (USD Million)
Table 78 Japan Heparin market, by end-use, 2018-2030 (USD Million)
Table 79 Japan Heparin market, by source, 2018-2030 (USD Million)
Table 80 India Heparin market, by type, 2018-2030 (USD Million)
Table 81 India Heparin market, by route of administration, 2018-2030 (USD Million)
Table 82 India Heparin market, by application, 2018-2030 (USD Million)
Table 83 India Heparin market, by end-use, 2018-2030 (USD Million)
Table 84 India Heparin market, by source, 2018-2030 (USD Million)
Table 85 South Korea Heparin market, by type, 2018-2030 (USD Million)
Table 86 South Korea Heparin market, by route of administration, 2018-2030 (USD Million)
Table 87 South Korea Heparin market, by application, 2018-2030 (USD Million)
Table 88 South Korea Heparin market, by end-use, 2018-2030 (USD Million)
Table 89 South Korea Heparin market, by source, 2018-2030 (USD Million)
Table 90 Australia Heparin market, by type, 2018-2030 (USD Million)
Table 91 Australia Heparin market, by route of administration, 2018-2030 (USD Million)
Table 92 Australia Heparin market, by application, 2018-2030 (USD Million)
Table 93 Australia Heparin market, by end-use, 2018-2030 (USD Million)
Table 94 Australia Heparin market, by source, 2018-2030 (USD Million)
Table 95 Thailand Heparin market, by type, 2018-2030 (USD Million)
Table 96 Thailand Heparin market, by route of administration, 2018-2030 (USD Million)
Table 97 Thailand Heparin market, by application, 2018-2030 (USD Million)
Table 98 Thailand Heparin market, by end-use, 2018-2030 (USD Million)
Table 99 Thailand Heparin market, by source, 2018-2030 (USD Million)
Table 100 Latin America Heparin market, by region, 2018-2030 (USD Million)
Table 101 Latin America Heparin market, by type, 2018-2030 (USD Million)
Table 102 Latin America Heparin market, by route of administration, 2018-2030 (USD Million)
Table 103 Latin America Heparin market, by application, 2018-2030 (USD Million)
Table 104 Latin America Heparin market, by end-use, 2018-2030 (USD Million)
Table 105 Latin America Heparin market, by source, 2018-2030 (USD Million)
Table 106 Brazil Heparin market, by type, 2018-2030 (USD Million)
Table 107 Brazil Heparin market, by route of administration, 2018-2030 (USD Million)
Table 108 Brazil Heparin market, by application, 2018-2030 (USD Million)
Table 109 Brazil Heparin market, by end-use, 2018-2030 (USD Million)
Table 110 Brazil Heparin market, by source, 2018-2030 (USD Million)
Table 111 Mexico Heparin market, by type, 2018-2030 (USD Million)
Table 112 Mexico Heparin market, by route of administration, 2018-2030 (USD Million)
Table 113 Mexico Heparin market, by application, 2018-2030 (USD Million)
Table 114 Mexico Heparin market, by end-use, 2018-2030 (USD Million)
Table 115 Mexico Heparin market, by source, 2018-2030 (USD Million)
Table 116 Argentina Heparin market, by type, 2018-2030 (USD Million)
Table 117 Argentina Heparin market, by route of administration, 2018-2030 (USD Million)
Table 118 Argentina Heparin market, by application, 2018-2030 (USD Million)
Table 119 Argentina Heparin market, by end-use, 2018-2030 (USD Million)
Table 120 Argentina Heparin market, by source, 2018-2030 (USD Million)
Table 121 MEA Heparin market, by region, 2018-2030 (USD Million)
Table 122 MEA Heparin market, by type, 2018-2030 (USD Million)
Table 123 MEA Heparin market, by route of administration, 2018-2030 (USD Million)
Table 124 MEA Heparin market, by application, 2018-2030 (USD Million)
Table 125 MEA Heparin market, by end-use, 2018-2030 (USD Million)
Table 126 MEA Heparin market, by source, 2018-2030 (USD Million)
Table 127 South Africa Heparin market, by type, 2018-2030 (USD Million)
Table 128 South Africa Heparin market, by route of administration, 2018-2030 (USD Million)
Table 129 South Africa Heparin market, by application, 2018-2030 (USD Million)
Table 130 South Africa Heparin market, by end-use, 2018-2030 (USD Million)
Table 131 South Africa Heparin market, by source, 2018-2030 (USD Million)
Table 132 Saudi Arabia Heparin market, by type, 2018-2030 (USD Million)
Table 133 Saudi Arabia Heparin market, by route of administration, 2018-2030 (USD Million)
Table 134 Saudi Arabia Heparin market, by application, 2018-2030 (USD Million)
Table 135 Saudi Arabia Heparin market, by end-use, 2018-2030 (USD Million)
Table 136 Saudi Arabia Heparin market, by source, 2018-2030 (USD Million)
Table 137 UAE Heparin market, by type, 2018-2030 (USD Million)
Table 138 UAE Heparin market, by route of administration, 2018-2030 (USD Million)
Table 139 UAE Heparin market, by application, 2018-2030 (USD Million)
Table 140 UAE Heparin market, by end-use, 2018-2030 (USD Million)
Table 141 UAE Heparin market, by source, 2018-2030 (USD Million)
Table 142 Kuwait Heparin market, by type, 2018-2030 (USD Million)
Table 143 Kuwait Heparin market, by route of administration, 2018-2030 (USD Million)
Table 144 Kuwait Heparin market, by application, 2018-2030 (USD Million)
Table 145 Kuwait Heparin market, by end-use, 2018-2030 (USD Million)
Table 146 Kuwait Heparin market, by source, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews in North America
Figure 5 Primary interviews in Europe
Figure 6 Primary interviews in APAC
Figure 7 Primary interviews in Latin America
Figure 8 Primary interviews in MEA
Figure 9 Market research approaches
Figure 10 Value-chain-based sizing & forecasting
Figure 11 QFD modeling for market share assessment
Figure 12 Market formulation & validation
Figure 13 Heparin market: market outlook
Figure 14 Heparin competitive insights
Figure 15 Parent market outlook
Figure 16 Related/ancillary market outlook
Figure 17 Penetration and growth prospect mapping
Figure 18 Industry value chain analysis
Figure 19 Heparin market driver impact
Figure 20 Heparin market restraint impact
Figure 21 Heparin market strategic initiatives analysis
Figure 22 Heparin market: Type movement analysis
Figure 23 Heparin market: Type outlook and key takeaways
Figure 24 Low molecular weight heparin market estimates and forecast, 2018-2030 (USD Million)
Figure 25 Ultra-low molecular weight heparin market estimates and forecast, 2018-2030 (USD Million)
Figure 26 Unfractionated Heparin market estimates and forecast, 2018-2030 (USD Million)
Figure 27 Heparin market: Route of Administration movement Analysis
Figure 28 Heparin market: Route of Administration outlook and key takeaways
Figure 29 Intravenous market estimates and forecasts, 2018-2030 (USD Million)
Figure 30 Subcutaneous market estimates and forecasts, 2018-2030 (USD Million)
Figure 31 Heparin market: Application movement analysis
Figure 32 Heparin market: Application outlook and key takeaways
Figure 33 Venous thromboembolism market estimates and forecasts, 2018-2030 (USD Million)
Figure 34 Atrial fibrillation market estimates and forecasts, 2018-2030 (USD Million)
Figure 35 Renal impairment market estimates and forecasts, 2018-2030 (USD Million)
Figure 36 Coronary artery disease market estimates and forecasts, 2018-2030 (USD Million)
Figure 37 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 38 Heparin market: End-use movement analysis
Figure 39 Heparin market: End-use outlook and key takeaways
Figure 40 Outpatient market estimates and forecasts, 2018-2030 (USD Million)
Figure 41 Inpatient market estimates and forecasts, 2018-2030 (USD Million)
Figure 42 Heparin market: Source movement analysis
Figure 43 Heparin market: Source outlook and key takeaways
Figure 44 Porcine market estimates and forecasts, 2018-2030 (USD Million)
Figure 45 Bovine market estimates and forecasts, 2018-2030 (USD Million)
Figure 46 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 47 Global Heparin market: Regional movement analysis
Figure 48 Global Heparin market: Regional outlook and key takeaways
Figure 49 Global Heparin market share and leading players
Figure 50 North America market share and leading players
Figure 51 Europe market share and leading players
Figure 52 Asia-Pacific market share and leading players
Figure 53 Latin America market share and leading players
Figure 54 Middle East & Africa market share and leading players
Figure 55 North America: SWOT
Figure 56 Europe SWOT
Figure 57 Asia-Pacific SWOT
Figure 58 Latin America SWOT
Figure 59 MEA SWOT
Figure 60 North America, by country
Figure 61 North America
Figure 62 North America market estimates and forecasts, 2018-2030 (USD Million)
Figure 63 U.S.
Figure 64 U.S. market estimates and forecasts, 2018-2030 (USD Million)
Figure 65 Canada
Figure 66 Canada market estimates and forecasts, 2018-2030 (USD Million)
Figure 67 Europe
Figure 68 Europe market estimates and forecasts, 2018-2030 (USD Million)
Figure 69 UK
Figure 70 UK market estimates and forecasts, 2018-2030 (USD Million)
Figure 71 Germany
Figure 72 Germany market estimates and forecasts, 2018-2030 (USD Million)
Figure 73 France
Figure 74 France market estimates and forecasts, 2018-2030 (USD Million)
Figure 75 Italy
Figure 76 Italy market estimates and forecasts, 2018-2030 (USD Million)
Figure 77 Spain
Figure 78 Spain market estimates and forecasts, 2018-2030 (USD Million)
Figure 79 Denmark
Figure 80 Denmark market estimates and forecasts, 2018-2030 (USD Million)
Figure 81 Sweden
Figure 82 Sweden market estimates and forecasts, 2018-2030 (USD Million)
Figure 83 Norway
Figure 84 Norway market estimates and forecasts, 2018-2030 (USD Million)
Figure 85 Asia-Pacific
Figure 86 Asia-Pacific market estimates and forecasts, 2018-2030 (USD Million)
Figure 87 China
Figure 88 China market estimates and forecasts, 2018-2030 (USD Million)
Figure 89 Japan
Figure 90 Japan market estimates and forecasts, 2018-2030 (USD Million)
Figure 91 India
Figure 92 India market estimates and forecasts, 2018-2030 (USD Million)
Figure 93 Thailand
Figure 94 Thailand market estimates and forecasts, 2018-2030 (USD Million)
Figure 95 South Korea
Figure 96 South Korea market estimates and forecasts, 2018-2030 (USD Million)
Figure 97 Australia
Figure 98 Australia market estimates and forecasts, 2018-2030 (USD Million)
Figure 99 Latin America
Figure 100 Latin America market estimates and forecasts, 2018-2030 (USD Million)
Figure 101 Brazil
Figure 102 Brazil market estimates and forecasts, 2018-2030 (USD Million)
Figure 103 Mexico
Figure 104 Mexico market estimates and forecasts, 2018-2030 (USD Million)
Figure 105 Argentina
Figure 106 Argentina market estimates and forecasts, 2018-2030 (USD Million)
Figure 107 Middle East and Africa
Figure 108 Middle East and Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 109 South Africa
Figure 110 South Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 111 Saudi Arabia
Figure 112 Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
Figure 113 UAE
Figure 114 UAE market estimates and forecasts, 2018-2030 (USD Million)
Figure 115 Kuwait
Figure 116 Kuwait market estimates and forecasts, 2018-2030 (USD Million)
Figure 117 Market share of key market players- Heparin market
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews in North America
Figure 5 Primary interviews in Europe
Figure 6 Primary interviews in APAC
Figure 7 Primary interviews in Latin America
Figure 8 Primary interviews in MEA
Figure 9 Market research approaches
Figure 10 Value-chain-based sizing & forecasting
Figure 11 QFD modeling for market share assessment
Figure 12 Market formulation & validation
Figure 13 Heparin market: market outlook
Figure 14 Heparin competitive insights
Figure 15 Parent market outlook
Figure 16 Related/ancillary market outlook
Figure 17 Penetration and growth prospect mapping
Figure 18 Industry value chain analysis
Figure 19 Heparin market driver impact
Figure 20 Heparin market restraint impact
Figure 21 Heparin market strategic initiatives analysis
Figure 22 Heparin market: Type movement analysis
Figure 23 Heparin market: Type outlook and key takeaways
Figure 24 Low molecular weight heparin market estimates and forecast, 2018-2030 (USD Million)
Figure 25 Ultra-low molecular weight heparin market estimates and forecast, 2018-2030 (USD Million)
Figure 26 Unfractionated Heparin market estimates and forecast, 2018-2030 (USD Million)
Figure 27 Heparin market: Route of Administration movement Analysis
Figure 28 Heparin market: Route of Administration outlook and key takeaways
Figure 29 Intravenous market estimates and forecasts, 2018-2030 (USD Million)
Figure 30 Subcutaneous market estimates and forecasts, 2018-2030 (USD Million)
Figure 31 Heparin market: Application movement analysis
Figure 32 Heparin market: Application outlook and key takeaways
Figure 33 Venous thromboembolism market estimates and forecasts, 2018-2030 (USD Million)
Figure 34 Atrial fibrillation market estimates and forecasts, 2018-2030 (USD Million)
Figure 35 Renal impairment market estimates and forecasts, 2018-2030 (USD Million)
Figure 36 Coronary artery disease market estimates and forecasts, 2018-2030 (USD Million)
Figure 37 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 38 Heparin market: End-use movement analysis
Figure 39 Heparin market: End-use outlook and key takeaways
Figure 40 Outpatient market estimates and forecasts, 2018-2030 (USD Million)
Figure 41 Inpatient market estimates and forecasts, 2018-2030 (USD Million)
Figure 42 Heparin market: Source movement analysis
Figure 43 Heparin market: Source outlook and key takeaways
Figure 44 Porcine market estimates and forecasts, 2018-2030 (USD Million)
Figure 45 Bovine market estimates and forecasts, 2018-2030 (USD Million)
Figure 46 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 47 Global Heparin market: Regional movement analysis
Figure 48 Global Heparin market: Regional outlook and key takeaways
Figure 49 Global Heparin market share and leading players
Figure 50 North America market share and leading players
Figure 51 Europe market share and leading players
Figure 52 Asia-Pacific market share and leading players
Figure 53 Latin America market share and leading players
Figure 54 Middle East & Africa market share and leading players
Figure 55 North America: SWOT
Figure 56 Europe SWOT
Figure 57 Asia-Pacific SWOT
Figure 58 Latin America SWOT
Figure 59 MEA SWOT
Figure 60 North America, by country
Figure 61 North America
Figure 62 North America market estimates and forecasts, 2018-2030 (USD Million)
Figure 63 U.S.
Figure 64 U.S. market estimates and forecasts, 2018-2030 (USD Million)
Figure 65 Canada
Figure 66 Canada market estimates and forecasts, 2018-2030 (USD Million)
Figure 67 Europe
Figure 68 Europe market estimates and forecasts, 2018-2030 (USD Million)
Figure 69 UK
Figure 70 UK market estimates and forecasts, 2018-2030 (USD Million)
Figure 71 Germany
Figure 72 Germany market estimates and forecasts, 2018-2030 (USD Million)
Figure 73 France
Figure 74 France market estimates and forecasts, 2018-2030 (USD Million)
Figure 75 Italy
Figure 76 Italy market estimates and forecasts, 2018-2030 (USD Million)
Figure 77 Spain
Figure 78 Spain market estimates and forecasts, 2018-2030 (USD Million)
Figure 79 Denmark
Figure 80 Denmark market estimates and forecasts, 2018-2030 (USD Million)
Figure 81 Sweden
Figure 82 Sweden market estimates and forecasts, 2018-2030 (USD Million)
Figure 83 Norway
Figure 84 Norway market estimates and forecasts, 2018-2030 (USD Million)
Figure 85 Asia-Pacific
Figure 86 Asia-Pacific market estimates and forecasts, 2018-2030 (USD Million)
Figure 87 China
Figure 88 China market estimates and forecasts, 2018-2030 (USD Million)
Figure 89 Japan
Figure 90 Japan market estimates and forecasts, 2018-2030 (USD Million)
Figure 91 India
Figure 92 India market estimates and forecasts, 2018-2030 (USD Million)
Figure 93 Thailand
Figure 94 Thailand market estimates and forecasts, 2018-2030 (USD Million)
Figure 95 South Korea
Figure 96 South Korea market estimates and forecasts, 2018-2030 (USD Million)
Figure 97 Australia
Figure 98 Australia market estimates and forecasts, 2018-2030 (USD Million)
Figure 99 Latin America
Figure 100 Latin America market estimates and forecasts, 2018-2030 (USD Million)
Figure 101 Brazil
Figure 102 Brazil market estimates and forecasts, 2018-2030 (USD Million)
Figure 103 Mexico
Figure 104 Mexico market estimates and forecasts, 2018-2030 (USD Million)
Figure 105 Argentina
Figure 106 Argentina market estimates and forecasts, 2018-2030 (USD Million)
Figure 107 Middle East and Africa
Figure 108 Middle East and Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 109 South Africa
Figure 110 South Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 111 Saudi Arabia
Figure 112 Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
Figure 113 UAE
Figure 114 UAE market estimates and forecasts, 2018-2030 (USD Million)
Figure 115 Kuwait
Figure 116 Kuwait market estimates and forecasts, 2018-2030 (USD Million)
Figure 117 Market share of key market players- Heparin market
Companies Mentioned
- Pfizer Inc.
- LEO Pharma A/S
- Dr. Reddy’s Laboratories Ltd.
- GlaxoSmithKline plc
- Sanofi
- Aspen Holdings
- Fresenius SE & Co. KGaA
- B. Braun Medical, Inc.
- Sandoz (Novartis AG)
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 111 |
| Published | December 2023 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 7.56 Billion |
| Forecasted Market Value ( USD | $ 9.03 Billion |
| Compound Annual Growth Rate | 2.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
